Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Chases Another Synthetic Stimulant Off Supplement Ingredient Menu

This article was originally published in The Tan Sheet

Executive Summary

CFSAN tells 14 firms the stimulant DMBA – identified by names including 1,3-dimethylbutylamine, 2-amino-4-methylpentane, AMP citrate and 4-methyl-2-pentanamine – has “no history of use or other evidence of safety … when used as a dietary ingredient.”

You may also be interested in...



Kirkman Acquires Rose, IQ Recalls Picamilon Supplement: Health And Wellness Industry News Roundup

Recalls reported by FDA for health and wellness products.

Hi-Tech Lawsuit Calls FDA DMAA Enforcement “Bullying Tactics”

Hi-Tech Pharmaceuticals files a lawsuit in federal court after receiving an administrative detention order from FDA to stop distributing its DMAA-containing products. The firm argues FDA should conduct a rulemaking to propose banning DMAA rather than ordering firms to stop using it.

US DoJ Has 'Key Focus' On Supplement Industry, Adds 6 Attorneys To Sector

"It is just common sense that there's going to be fraud where you have the combination of high growth, developing science, imported products or ingredients and limited oversight," says David Morrell, deputy assistant US attorney in DoJ'd Consumer Protection Branch. CPB is adhering to executive order President Trump made earlier in 2019 instructing federal agencies to enforced based on regulations, not on guidance.

Topics

UsernamePublicRestriction

Register

PS107645

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel